SuperworthElutia price to sales ratio ELUT
Market value divided by revenue over the last twelve months, since 2021.
- Today, Oct 23, 2026
- 3.1×
- 5-year median
- 2.0×
- Against its 5-year history
- 76th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.4× to 6.8×
- Peer median
- 1.4×
Elutia's price to sales ratio is 3.1× as of Oct 23, 2026.
That is above its 5-year median of 2.0×, higher than on 76% of days in the last 5 years.
Over that time it ranged from 0.4× in Sep 2023 to 6.8× in Dec 2024.
The median for 10 healthcare stocks of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.1× | 1.3× | 3.5× |
| 2025 | 1.1× | 1.1× | 5.3× |
| 2024 | 5.5× | 1.7× | 6.8× |
| 2023 | 1.2× | 0.4× | 1.4× |
| 2022 | 1.2× | 1.0× | 2.4× |
| 2021 | 1.3× | 0.9× | 1.9× |
Against its peers
Companies in Healthcare nearest Elutia's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ELUTElutia | 3.1× |
| NEPHNephros | 1.9× |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 0.3× |
| PDEXPro DEX | 2.6× |
| PLXProtalix BioTherapeutics | 2.5× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 1.4× |
Where Elutia ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Elutia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.